Skip to main content
Erschienen in: BMC Nephrology 1/2022

Open Access 01.12.2022 | Research

Conservative therapy is associated with worse clinical features and biochemical derangements than renal replacement therapy: a retrospective study in Kumasi, Ghana

verfasst von: Perditer Okyere, Isaac Okyere, Grace Essuman, Joseph Attakora, Dorcas Serwaa, Irene Esi Donkoh, Richard K.D. Ephraim

Erschienen in: BMC Nephrology | Ausgabe 1/2022

Abstract

Background

The incidence of end stage kidney disease (ESKD) is increasing in Ghana as with the rest of the world. This study compared the sociodemographic, diagnostic characteristics (clinical, biochemical and imaging) and clinical outcomes of ESKD patients who chose either renal replacement therapy (RRT) or conservative therapy as well as the factors that influenced their choice.

Methods

We retrospectively reviewed the records of 382 ESKD patient from 2006 to 2018. The data was collected from the Nephrology Clinic at the Komfo Anokye Teaching Hospital (KATH). Sociodemographic, diagnostic (clinical, biochemical and imaging) and therapeutic data were obtained, organized and analyzed with Statistical Package for the Social Sciences (SPSS).

Results

Of the 382 patients, 321 had conservative therapy whiles 61 had renal replacement therapy. The mean age of participants was 47.71 ± 16.10 years. Bipedal swelling (16.8%), fatigue (10.4%) and facial swelling (9.2%) were the major clinical features. Chronic glomerulonephritis (31.4%), hypertension (30.3%) and diabetes mellitus nephropathy (28.2%) were the most frequent predisposing conditions. Nifedipine (82.0%), bisoprolol (32.8%), aspirin (19.7%), ranitidine (26.2%), metformin (13.1%) and lasix (78.7%) were commonly used by the RRT patients than their conservative therapy counterparts. Compared to their RRT counterparts, patients on conservative therapy were more on irbesartan/lisinopril (57.9%) and sodium hydro carbonate (NaHCO3) (52.0%). Diastolic blood pressure (DBP) (p = 0.047), uremic gastritis (p = 0.007), anaemia, uraemia, haematuria and hyperkalaemia (p < 0.001) were more common in conservative therapy patients than RRT patients with RRT patients showing better corticomedullary differentiation (38.1% vs. 27.7%, p < 0.001) and normal echotexture (15.0% vs. 11.6%, p = 0.005). Age, gender, occupation and duration of illness were significantly associated with the decision to opt for conservative therapy.

Conclusion

Patients on conservative therapy have worse clinical outcomes than their RRT counterparts. Early referrals to nephrologist as well as subsidized RRT should be targeted.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

The incidence of Chronic Kidney Disease (CKD) is increasing in Ghana [1, 2] as with the rest of the world [36]. It is a growing global health issue and is associated with high morbidity and mortality [7]. Risk factors of CKD includes obesity, hypertension, diabetes mellitus, HIV (Human Immunodeficiency Virus) among others [3, 8, 9]. Complications such as gout, anemia, cardiovascular disease occur as the disease progresses which greatly increases morbidity [10, 11].
As CKD advance to end stage kidney disease (ESKD), patients may choose either conservative therapy or renal replacement therapy (RRT) for the continual management. Conservative therapy involves treating symptoms, efforts to control complications and palliative care. This decision, in consensus with caregivers, is ideally chosen for aged patients [12, 13]. RRT includes hemodiafiltration, hemodialysis, kidney transplantation and peritoneal dialysis. These are engaged in critical acute kidney injury, ESKD or in acute kidney injury superimposed on chronic kidney disease. [14]
The management of this condition is highly burdensome as it takes a heavy toll on both the financial and emotional well-being of both patients and loved ones. In sub-Saharan Africa, the outcome of ESKD is rather poor because the resources and expertise needed for combating the disease are scarce and there is limited awareness of the disease and its risk factors. Per se, there is the need to concentrate more efforts on improving the disease outcomes. In some countries, RRT and conservative care regimes are being closely monitored [1519] to determine which treatment regimen is better suited for their citizens. Currently, no study has been conducted in Ghana to analyze the patterns of ESKD management of which this study sought to accomplish. We compared the sociodemographic features, diagnostic characteristics (clinical, biochemical and imaging) and clinical outcomes of ESKD patients who chose either RRT or conservative therapy as well as the factors that influenced their choice.

Methodology

Study design

We retrospectively reviewed the records of 382 ESKD patient from 2006 to 2018. The data was collected from the Nephrology Clinic at the Komfo Anokye Teaching Hospital (KATH). KATH, the second largest public hospital in Ghana with 1000 bed capacity and has one of the only six public dialysis centers in the country.

Eligibility criteria

ESKD patient records within the period under review was used. CKD patients who had not reached stage 5 ESKD and patients with incomplete data were excluded.

Data collection

Data of 382 ESKD patients from 2006 to 2018 (male/female) was manually collected from the records of the nephrology unit and sifted through to obtain demographic information including: gender, age, religion and occupation as well as clinical information including: cause of ESKD, symptoms presented, presence or absence of hypertension and/or diabetes mellitus, results of biochemical tests, treatment administered and ultrasound results of each patient.

Ethical consideration

Ethical clearance for the study was obtained from the research and development unit of KATH. Data used was obtained in adherence to the principles of the declaration of Helsinki and local regulatory requirements. Informed consent was obtained from all participants of the study.

Data analysis

Statistical Package for the Social Science (SPSS; IBM, USA) Version 22 was used for all statistical analyses. For demographic factors, descriptive statistics was used. For categorical variables, the results were represented as a percentage (%) or a number (n), and for continuous variables, means SD) or median (interquartile range). For categorical variables, the chi-square test or Fisher exact test was used, and for continuous variables, the t test or Mann–Whitney U test was used, as applicable. To find associated factors with outcome variables, a binary logistic regression analysis was performed and all independent variables with p < 0.05 were submitted to a multivariable logistic regression analysis. The adjusted odds ratio was considered statistically significant at p < 0.05 and 95% confidence level in the final model. The threshold for statistical significance was fixed at p < 0.05.

Results

This study involved 382 ESKD patients of which 61/382(16%) underwent renal replacement therapy (RRT) while 321/382 (84%) were put on conservative treatment. The mean (SD) age of the participants was 47.71 ± 16.10 years. Both RRT and conservative groups had more males (68.9% vs. 57.9%, p < 0.001), Christians (88.5% vs. 91.6%, p < 0.001) and employed within the informal sector (46.4% vs. 57.5%, p < 0.001).
Table 1
Sociodemographic characteristics of the study participants
Baseline characteristics
All patients
Renal replacement therapy group
Conservative group
P-value
Age (years)
N (%)
N (%)
N (%)
 
10–24
45 (11.8)
2 (3.3)
43 (13.4)
< 0.001
25–39
76 (19.9)
12 (19.9)
64 (19.9)
< 0.001
40–54
114 (29.8)
25 (41.0)
89 (27.7)
< 0.001
55–69
118 (30.9)
19(31.1)
99(30.8)
< 0.001
≥ 70
29 (7.6)
3(4.9)
26(8.1)
< 0.001
Gender
    
Female
154(40.3)
19(31.1)
135(42.1)
< 0.001
Male
228(59.7)
42(68.9)
186(57.9)
< 0.001
Religion
    
Muslim
34(8.9)
7(11.5)
27(8.4)
0.001
Christian
348(91.1)
53(88.5)
294(91.6)
< 0.001
Occupation
    
unemployed
62(18.1)
10(17.9)
52(18.1)
< 0.001
students
32(9.9)
3(5.4)
31(10.8)
< 0.001
Pensioners
17(5.0)
2(3.6)
15(5.2)
0.002
Informal sector
192(56.0)
26(46.4)
166(57.8)
< 0.001
Formal sector
38(11.1)
15(26.8)
23(8.0)
0.194
Duration of illness (months)
< 1
46(24.3)
10(47.6)
36(21.4)
< 0.001
1–5
119(63.0)
8(38.1)
111(66.1)
< 0.001
> 6
24(12.7)
3(14.3)
21(12.5)
< 0.001
The presenting complaints of the study patients are enumerated in Fig. 1. The major clinical features were bipedal swelling in 60/357 (16.8%), followed by easy fatigability in 37/357 (10.4%) and CKD in 33/357 (9.2%) patients. Thirty-two patients (9.2%), 29/357 (8.1%) and 18/ 357 (5.0%) presented with early morning facial swelling, breathlessness and pedal swellings respectively.
Hypertension (59.6% vs. 56.8%, p < 0.001) and hypertensive plus diabetes mellitus (32.7% vs. 28.0%, p < 0.001) were significant in RRT group contrary to the conservative group. The two groups also differed in their therapeutic characteristics as well as the comorbidities presented at diagnosis as summarized in Table 2.
Table 2
Cause of diagnosis, co-morbidity and therapeutic characteristics of the study patients
Variables
All patients
Renal replacement therapy group
Conservative group
P-value
 
N (%)
N (%)
N (%)
 
Cause of diagnosis
    
CGN
119(31.4)
12(20.3)
107(33.4)
< 0.001
Hypertension
115(30.3)
19(32.2)
96(30.0)
< 0.001
Diabetes mellitus nephropathy
107(28.2)
24(40.7)
83(25.9)
< 0.001
HIVAN
12(3.2)
0(0.0)
12(3.8)
-
ADPKD
10(2.6)
3(5.1)
7(2.2)
0.206
Obstructive uropathy
8(2.1)
1(1.7)
7(2.2)
0.034
Othersa
8(2.1)
0(0.0)
8(2.5)
-
Co-morbid at the time of presentation
Hypertension
169(57.3)
31(59.6)
138(56.8)
< 0.001
Diabetes mellitus
20(6.8)
4(7.7)
16(6.6)
0.007
Hypertension with Diabetes Mellitus
85(28.8)
17(32.7)
68(28.0)
< 0.001
HIV
13(4.4)
0(0.0)
13(5.3)
-
Othersb
8(2.7)
0(0.0)
8(3.3)
-
Medications (yes)
Nifedipine
288(75.4)
50(82.0)
238(74.1)
< 0.001
Irbesartan/Lisinopril
218(57.1)
32(52.5)
186(57.9)
< 0.001
Bisoprolol
61(16.0)
20(32.8)
41(12.8)
0.007
Aspirin
41(10.7)
12(19.7)
29(9.0)
0.008
Prednisolone
14(3.7)
4(6.6)
10(3.1)
0.109
Ranitidine
70(18.3)
16(26.2)
54(16.8)
< 0.001
Metformin
34(8.9)
8(13.1)
26(8.1)
0.002
Gliclazide
382(100.0)
61(100.0)
321(100.0)
< 0.001
Lasix
295(77.2)
48(78.7)
247(76.9)
< 0.001
Hydralazine
139(36.4)
32(52.5)
107(33.3)
< 0.001
Methyldopa
191(50.0)
32(55.7)
157(48.9)
< 0.001
EPO
35(9.2)
17(27.9)
18(5.6)
0.866
CaCO3
242(63.4)
39(63.9)
203(63.2)
< 0.001
NaHCO3
193(50.5)
26(42.6)
167(52.0)
< 0.001
Statin
92(24.1)
19(31.1)
73(22.7)
< 0.001
CGN: chronic glomerulonephritis, HIVAN: HIV associated nephropathy, HIV: human immunodeficiency virus, ADPKD: autosomal dominant polycystic kidney disease, EPO: erythropoietin, CaCO3: Calcium carbonate, NaHCO3: Sodium hydro carbonate, Othersa : Benign Prostatic Hyperplasia, Bilateral Vascular Failure, Diabetes Mellitus/Sickle Cell, Hepatitis B/HIV, Hypertension/Stroke, Sickle cell, Othersb : Chronic Interstitial nephritis, Chronic schistosomiasis, HIV, Multiple myeloma, Renal oncocytoma, Uremic gastritis, SC nephropathy
Table 3 indicates that the median diastolic blood pressure and urea levels were significantly higher in the conservative treatment group compared with the RRT group. The chi square test also revealed that more RRT patients tested positive for protein in urine than the conservative treatment group (93.1% vs. 92.0%, p < 0.001). However, the conservative treatment group compared to the RRT group tested positive for blood in urine (56.4% vs. 50.0%, p < 0.001). There were no significant differences in SBP, hemoglobin, white blood cell count, MCV, MCH, sodium, potassium, triglycerides, LDL-c, HDL-c, VLDL-c, cholesterol, creatinine levels and eGFR between the two groups.
Table 3
Baseline Clinical and Laboratory investigation results of the patients before treatment
Parameters
All Subjects
Renal replacement therapy group
Conservative group
P value
 
mean ± SD/ Median [IQR]
Mean ± SD/Median [IQR]
mean ± SD/Median [IQR]
 
SBP (mmHg)
154.85 ± 25.1
152.6 ± 25.3
155.3 ± 25.1
0.459
DBP (mmHg)
90.0 [79.0-100.0]
83.3 [78.3–93.8]
90.0 [79.3-100.1]
0.047
Haemoglobin
8.0 [6.9–9.2]
8.3 [7.2–9.1]
7.9 [6.8–9.2]
0.309
White Blood Count
5.6 [4.6–7.1]
5.8 [5.0-7.2]
5.6 [4.5–7.1]
0.136
MCV
82.6 ± 6.8
83.11 ± 6.4
82.5 ± 6.9
0.557
MCH
27.67 ± 2.6
27.7 ± 2.6
27.7 ± 2.6
0.858
Sodium
135.7 [132.6–138.0]
136.0 [136.0-139.0]
135.5 [131.6–138.0]
0.159
Potassium
5.0 [4.5–5.6]
4.9 [4.0-5.4]
5.1 [4.5–5.6]
0.093
Urea
28.0 [20.0-37.4]
22.2 [15.0-30.3]
28.6 [20.9–38.0]
0.001
Triglycerides
1.3 [1.0-1.8]
1.2 [1.0-1.5]
1.3 [1.0–2.0]
0.566
LDL-c
3.1 [2.2–3.8]
2.9 [2.0-4.1]
3.1 [2.3–3.8]
0.809
HDL-c
1.2 [0.8–1.5]
1.2 [0.8–1.6]
1.1 [0.8–1.4]
0.945
VLDL-c
0.6 [0.4-1.0]
0.6 [0.4–0.8]
0.6 [0.5–1.1]
0.368
Cholesterol
5.0 [3.9–5.8]
5.0 [3.6–6.1]
5.0 [4.0-5.8]
0.593
Creatinine
1095.0 [703.4-1581.5]
1004.5 [570.8-1678.8]
1116.9 [714.0-1563.0]
0.333
eGFR
4.0 [3.0–7.0]
5.0 [3.0-8.3]
4.0 [3.0–7.0]
0.433
Positive
N (%)
N (%)
N (%)
 
Urine Protein
187(92.1)
27(93.1)
160(92.0)
< 0.001
Urine Blood
105(55.6)
12(50.0)
93(56.4)
< 0.001
SBP: systolic blood pressure, DBP: diastolic blood pressure, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, LDL-c: low density lipoprotein cholesterol, HDL-c: high density lipoprotein cholesterol, VLDL-c: very low-density lipoprotein cholesterol, eGFR: estimated glomerular filtration rate
The complications after dialysis, conservative treatment and treatment outcomes are summarized in Table 4. Relative to the RRT group, more conservative group patients developed anemia (57.3% vs. 55.7%, p < 0.001), hyperkalemia (11.5% vs. 4.9%, p < 0.001) and uremic gastritis (3.1% vs. 1.6%, p = 0.007). However, the RRT patients had more fluid overload (18.0% vs. 12.8%, p < 0.001) and pulmonary edema (8.2% vs. 6.3% p < 0.001) compared with the conservative group.
Table 4
Complications after treatment and outcome in the study participants
 
All patients
Renal replacement therapy group
Conservative group
p-value
 
N (%)
N (%)
N (%)
 
Complications
    
Anaemia
218(57.1)
34(55.7)
184(57.3)
< 0.001
Fluid Overload
52(13.6)
11(18.0)
41(12.8)
< 0.001
Hyperkalaemia
40(10.5)
3(4.9)
37(11.5)
< 0.001
Pulmonary oedema
29(7.6)
5(8.2)
24(6.3)
< 0.001
Uncontrolled hypertension
24(6.3)
6(9.8)
18(5.6)
0.014
Uremic Gastritis
11(2.9)
1(1.6)
10(3.1)
0.007
Uremic encephalopathy
7(1.8)
1(1.6)
6(1.9)
0.059
Acute rejection
1(0.3)
0(0.0)
1(0.3)
-
Outcome
    
Dead
8(2.1)
6(9.8)
2(0.6)
0.289
Alive
30(7.3)
12(19.7)
18(5.6)
0.273
Lost to follow-up
337(88.2)
41(67.2)
296(92.2)
< 0.001
Others
7(1.8)
2(3.3)
5(1.6)
0.045
In the bivariate logistic regression (first model), patients aged 40–54 years had lower odds of undergoing conservative treatment compared with those aged 10–24 years (OR: 0.242, 95% C.I. 0.037,0.731). Formal sector workers had less likelihood of opting for conservative treatment compared to unemployed patients (OR: 0.295, 95% C.I. 0.155, 0.754). The likelihood of undergoing conservative treatment was higher among patients diagnosed with ESKD within 1–5 months compared with those diagnosed in < 1 month (AOR: 3.854, 95% CI; 1.414, 10.506). Gender and occupation of the patients were not associated with the decision to opt for conservative treatment(p > 0.05). Controlling for confounding factors in the multivariate analysis, only duration of illness was significantly associated with the choice for conservative treatment option among the study participants. Thus, patients who were diagnosed within 1–5 months had higher likelihood of opting for conservative treatment compared with those diagnosed in < 1 month (AOR: 4.52, 95% CI; 1.350,15.162) (Table 5).
Table 5
Variables associated with the decision to undergo of conservative treatment
 
Bivariate analysis
Multivariate analysis
 
OR (95% CI)
p-value
OR (95% CI)
p-value
Age [ref: 10–24 years]
    
25–39
0.248(0.053,1.164)
0.077
0.257(0.014,4.620)
0.356
40–54
0.166(0.037,0.731)
0.018*
0.075(0.003,1.609)
0.098
55–69
0.242(0.054,1.087)
0.064
0.109(0.005,2.2860)
0.153
≥ 70
0.403(0.063,2.575)
0.337
_-
-
Gender [ref: Female]
    
Male
0.623(0.347,1.119)
0.113
0.517(0.165,1.618)
0.257
Religion [ref: Muslim]
    
Christian
1.412(0.585,3.405)
0.443
-
-
Occupation [ref: unemployed]
    
students
1.987(0.508,7.779)
0.324
-
-
Pensioners
1.442(0.285,7.312)
0.658
-
-
Informal sector
1.228(0.556,2.714)
0.612
-
-
Formal sector
0.295(0.155,0.754)
0.011*
1.547(0.262,9.144)
0.630
Duration of illness [ref: <1 month]
1–5
3.854(1.414,10.506)
0.008*
4.524(1.350,15.162)
0.014*
> 6
1.944(0.480,7.869)
0.351
-
-

Discussion

This study compared the sociodemographic features, diagnostic characteristics (clinical, biochemical and imaging) and clinical outcomes of ESKD patients who chose either RRT or conservative therapy as well as the factors that influenced their choice. Bipedal swelling (16.8%), fatigue (10.4%) and facial swelling (9.2%) were the major clinical features. Chronic glomerulonephritis (31.4%), hypertension (30.3%) and diabetes mellitus nephropathy (28.2%) were the most frequent predisposing conditions. Nifedipine (82.0%), bisoprolol (32.8%), aspirin (19.7%), ranitidine (26.2%), metformin (13.1%) and lasix (78.7%) were commonly used by the RRT patients than their conservative therapy counterparts. Compared to their RRT counterparts, patients on conservative therapy were more on irbesartan/lisinopril (57.9%) and sodium hydro carbonate (NaHCO3) (52.0%). Diastolic blood pressure (DBP) (p = 0.047), uremic gastritis (p = 0.007), anaemia, uraemia, haematuria and hyperkalaemia (p < 0.001) were more common in conservative therapy patients than RRT patients with RRT patients showing better corticomedullary differentiation (38.1% vs. 27.7%, p < 0.001) and normal echotexture (15.0% vs. 11.6%, p = 0.005). In agreement with previous studies, majority of our participants were aged 40–69 years with a male preponderance [20, 21]. ESKD is known to occur in advanced ages where risk factors are high with more comorbidities [22]. The male preponderance is likely due to hypertension, a major risk factor, occurring more in males than in females with the incidence of uncontrolled BP often in males[23]. Male prevalence in incidents of primary renal diseases [11, 24] also plays a role.
At diagnosis, the most prevalent causes of ESKD were CGN, hypertension and diabetes nephropathy (Table 2) with majority of the participants presenting with pedal, facial and bodily swelling as well as fatigue (Fig. 1) as observed in other studies [25][20]. Conservative therapy patients had higher occurrence of uremia, hyperkalemia and hematuria with more DBP measurements. A lot of these patients were on ACEis/ARBs which are known to reduce GFR and cause some electrolyte imbalances as their adverse effects [26] could explain the uremia and hyperkalemia observed.
Complications like uncontrolled hypertension, anemia (Table 4) and hematuria (Table 3) are all associated with ESKD progression [5][27][10]. Hence, from our data, we can infer that disease progression is faster in the conservative therapy participants than the RRT participants. Ergo, the RRT patients showed better corticomedullary differentiation and normal echotexture (Table 5). Nevertheless, some complications such as fluid overload and pulmonary edema slightly dominated in the RRT patients. These are common occurrences in dialysis patients [28, 29] mostly resulting from inaccuracies in the dialysis process and patient lifestyle [30].
One major objective in CKD and ESKD management is to control BP to a target level of < 130/80 mmHg [27], which is why blood pressure drugs dominated among the medication administered. Nifedipine (a calcium channel blocker) was the most used BP drug among hydralazine, methyldopa and bisoprolol in both groups because they are highly bound and excreted through hepatic metabolism hence unaffected by kidney dysfunction. Other drugs administered include gliclazide and metformin for Type 2 diabetes mellitus, CaCO3, fersolate and folic acid as nutrient supplements, aspirin and prednisolone for pain and allergies among others.
Ideally, ESKD is managed with dialysis or kidney transplantation and sometimes conservative therapy for very old patients with many comorbidities [31]. We noted that none of our participants had kidney transplant. Also, majority of our patients were on conservative therapy rather than RRT (Table 1). This finding proves the point made by Antwi, (2015) [2] that “the current state of RRT services in Ghana is inadequate and calls for serious national consideration”. In his paper, he attributed this to several reasons including limited dialysis facilities in the country, unavailability of insurance schemes to cover cost despite the high cost of these therapies and lack of constant electricity supply. We conducted this study in one of the only 6 public dialysis centers available in the country, all of which are in the southern zone. This shows how scarce the treatment is to the general public especially those in the northern and central zones. Most people who opt for RRT may have to travel several kilometers away from home to access treatment. Considering the fact that majority of our participants are either unemployed or in the informal sector (Table 1) and with the unavailability of insurance coverage for citizens, the collective cost of travelling, laboratory investigations, drugs as well as dialysis sessions is unaffordable to most of them and they would have to settle for conservative therapy.
From Table 4, we noticed that age and gender are variables significantly associated with the decision to opt for conservative therapy. Looking at the majority age range (40–69 years) with most being males, it is likely that these individuals are breadwinners with many financial responsibilities and may not have the luxury or support to finance RRT. Duration of illness was also a significant variable; more of the patients who had had the disease for longer periods opted for conservative therapy. This is likely because hemodialysis is an awfully burdensome intervention especially in Ghana and chronic hemodialysis patients often opt out and resort to conservative care as disease progresses and resources are depleted.
A major limitation in our study was that some participants did not complete their data and were disqualified. Thus, we lost about 80% of our participants to follow up and we could also not access and contrast the quality of life of both groups during treatment.

Conclusion

In this study, ESKD progression occurred faster in patients who opted for conservative therapy because it was associated with worse clinical features and biochemical derangements than Renal Replacement Therapy. The major factors that influenced the choice of either RRT or conservative care were age, gender and duration of illness. Duration of illness was the only significant factor after controlling for the other variables. Hence early referrals to the nephrologist should be encouraged. Also, policy makers should aim at increasing dialysis centers in the country while providing substantial financial support to chronic dialysis patients.

Acknowledgements

We acknowledge the immense role of the staff of the records department in making this work a great success]

Declarations

The study was approved by the Committee of Heath Research Publications and Ethics of the Komfo Anokye Teaching Hospital. Data used was obtained in adherence to the principles of the declaration of Helsinki and local regulatory requirements. Informed consent was obtained from all participants of the study.
Not Applicable.

Competing interests

Authors declare no competing interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Amoako YA, Laryea DO, Bedu-Addo G, Andoh H, Awuku YA. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. Pan Afr Med J. 2014;18. Amoako YA, Laryea DO, Bedu-Addo G, Andoh H, Awuku YA. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. Pan Afr Med J. 2014;18.
2.
Zurück zum Zitat Antwi S. State of renal replacement therapy services in Ghana. Blood Purif. 2015;39(1–3):137–40.CrossRefPubMed Antwi S. State of renal replacement therapy services in Ghana. Blood Purif. 2015;39(1–3):137–40.CrossRefPubMed
3.
Zurück zum Zitat Kakitapalli Y, Ampolu J, Madasu SD. S SKML. Detailed Review of Chronic Kidney Disease. 2020;85–91. Kakitapalli Y, Ampolu J, Madasu SD. S SKML. Detailed Review of Chronic Kidney Disease. 2020;85–91.
4.
Zurück zum Zitat Bear RA, Stockie S. Patient engagement and patient-centred care in the management of advanced chronic kidney disease and chronic kidney failure. 2014;1–8. Bear RA, Stockie S. Patient engagement and patient-centred care in the management of advanced chronic kidney disease and chronic kidney failure. 2014;1–8.
5.
Zurück zum Zitat Orlandi PF, Fujii N, Roy J, Chen HY, Lee Hamm L, Sondheimer JH, et al. Hematuria as a risk factor for progression of chronic kidney disease and death: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. BMC Nephrol. 2018;19(1):1–11.CrossRef Orlandi PF, Fujii N, Roy J, Chen HY, Lee Hamm L, Sondheimer JH, et al. Hematuria as a risk factor for progression of chronic kidney disease and death: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. BMC Nephrol. 2018;19(1):1–11.CrossRef
6.
Zurück zum Zitat Ruiz-Arenas R, Sierra-Amor R, Seccombe D, Raymondo S, Graziani MS, Panteghini M, et al. A summary of worldwide national activities in Chronic Kidney Disease (CKD) testing. Ejifcc. 2017;28(4):302.PubMedPubMedCentral Ruiz-Arenas R, Sierra-Amor R, Seccombe D, Raymondo S, Graziani MS, Panteghini M, et al. A summary of worldwide national activities in Chronic Kidney Disease (CKD) testing. Ejifcc. 2017;28(4):302.PubMedPubMedCentral
7.
Zurück zum Zitat Hood SA, Sondheimer JH. Impact of Pre-ESRD Management on Dialysis Outcomes: A Review. 1993. Hood SA, Sondheimer JH. Impact of Pre-ESRD Management on Dialysis Outcomes: A Review. 1993.
9.
Zurück zum Zitat Sumida K, Kovesdy CP. Disease Trajectories Before ESRD_ Implications for Clinical Management. Semin Nephrol. 2017;37(2):132–43.CrossRefPubMed Sumida K, Kovesdy CP. Disease Trajectories Before ESRD_ Implications for Clinical Management. Semin Nephrol. 2017;37(2):132–43.CrossRefPubMed
10.
Zurück zum Zitat Hynes DM, Stroupe KT, Kaufman JS, Reda DJ, Peterman A, Browning MM, et al. Adherence to Guidelines for ESRD Anemia Management. 2006;47(3):455–61. Hynes DM, Stroupe KT, Kaufman JS, Reda DJ, Peterman A, Browning MM, et al. Adherence to Guidelines for ESRD Anemia Management. 2006;47(3):455–61.
11.
Zurück zum Zitat Weigert A, Drozdz M, Silva F, Frazão J, Alsuwaida A, Krishnan M, et al. Influence of gender and age on haemodialysis practices: A European multicentre analysis. Clin Kidney J. 2019;13(2):217–24.CrossRefPubMedPubMedCentral Weigert A, Drozdz M, Silva F, Frazão J, Alsuwaida A, Krishnan M, et al. Influence of gender and age on haemodialysis practices: A European multicentre analysis. Clin Kidney J. 2019;13(2):217–24.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Carson RC, Juszczak M, Davenport A, Burns A. Is Maximum Conservative Management an Equivalent Treatment Option to Dialysis for Elderly Patients with Significant Comorbid Disease ?:1611–9. Carson RC, Juszczak M, Davenport A, Burns A. Is Maximum Conservative Management an Equivalent Treatment Option to Dialysis for Elderly Patients with Significant Comorbid Disease ?:1611–9.
13.
Zurück zum Zitat Williams B, Mcdaid R, Walker R, Quarterly R, Cross J, Burns A. Maximum Conservative Management of End Stage Renal Failure. What Can Patients and Their Families Expect? In: Conference abstract—The Renal Association Annual Conference London: October. 2002. Williams B, Mcdaid R, Walker R, Quarterly R, Cross J, Burns A. Maximum Conservative Management of End Stage Renal Failure. What Can Patients and Their Families Expect? In: Conference abstract—The Renal Association Annual Conference London: October. 2002.
14.
Zurück zum Zitat Britain) NCC for CC (Great. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. In Royal College of Physicians; 2008. Britain) NCC for CC (Great. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. In Royal College of Physicians; 2008.
15.
Zurück zum Zitat Tamura MK, Meier DE. Commentary Five Policies to Promote Palliative Care for Patients with ESRD. 2013;1783–90. Tamura MK, Meier DE. Commentary Five Policies to Promote Palliative Care for Patients with ESRD. 2013;1783–90.
16.
Zurück zum Zitat Tamura MK, Hare AMO, Lin E, Holdsworth LM, Malcolm E, Moss AH. Palliative Care Disincentives in CKD: Changing Policy to Improve CKD Care. Am J Kidney Dis. 2018;71(6):866–73.CrossRefPubMedCentral Tamura MK, Hare AMO, Lin E, Holdsworth LM, Malcolm E, Moss AH. Palliative Care Disincentives in CKD: Changing Policy to Improve CKD Care. Am J Kidney Dis. 2018;71(6):866–73.CrossRefPubMedCentral
17.
Zurück zum Zitat Rak A, Raina R, Suh TT, Krishnappa V, Darusz J, Sidoti CW, et al. Palliative care for patients with end-stage renal disease: approach to treatment that aims to improve quality of life and relieve suffering for patients (and families) with chronic illnesses *. 2017;10(1):68–73. Rak A, Raina R, Suh TT, Krishnappa V, Darusz J, Sidoti CW, et al. Palliative care for patients with end-stage renal disease: approach to treatment that aims to improve quality of life and relieve suffering for patients (and families) with chronic illnesses *. 2017;10(1):68–73.
18.
Zurück zum Zitat Davison SN. Ethics Series The Ethics of End-of-Life Care for Patients with ESRD. 2012;2049–57. Davison SN. Ethics Series The Ethics of End-of-Life Care for Patients with ESRD. 2012;2049–57.
19.
Zurück zum Zitat Morton RL, Webster AC, Mcgeechan K, Howard K, Murtagh FEM, Gray NA, et al. Article Conservative Management and End-of-Life Care in an Australian Cohort with ESRD. 2016;2195–203. Morton RL, Webster AC, Mcgeechan K, Howard K, Murtagh FEM, Gray NA, et al. Article Conservative Management and End-of-Life Care in an Australian Cohort with ESRD. 2016;2195–203.
20.
Zurück zum Zitat State O. The pattern, clinical characteristics and outcome of ESRD in Ile-Ife, Nigeria : Is there a change in trend ? 2011;11(4). State O. The pattern, clinical characteristics and outcome of ESRD in Ile-Ife, Nigeria : Is there a change in trend ? 2011;11(4).
21.
Zurück zum Zitat Dialysis FOF. Hemodialysis. Management problems in developing countries. with Nigeria as a surrogate. 2003;63:93–5. Dialysis FOF. Hemodialysis. Management problems in developing countries. with Nigeria as a surrogate. 2003;63:93–5.
22.
Zurück zum Zitat Davison SN, Sc M. The Prevalence and Management of Chronic Pain. 2007;10(6). Davison SN, Sc M. The Prevalence and Management of Chronic Pain. 2007;10(6).
23.
Zurück zum Zitat Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144(7):475–84.CrossRefPubMedPubMedCentral Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144(7):475–84.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Ishikawa I, Maeda K, Nakai S, Kawaguchi Y. Gender difference in the mean age at the induction of hemodialysis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35(6):1072–5.CrossRefPubMed Ishikawa I, Maeda K, Nakai S, Kawaguchi Y. Gender difference in the mean age at the induction of hemodialysis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35(6):1072–5.CrossRefPubMed
25.
Zurück zum Zitat Education M. End-stage renal disease in India and Pakistan: Burden of disease and management issues. 2003;63:115–8. Education M. End-stage renal disease in India and Pakistan: Burden of disease and management issues. 2003;63:115–8.
26.
Zurück zum Zitat Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601–7.CrossRefPubMed Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601–7.CrossRefPubMed
27.
Zurück zum Zitat Lee H-Y, Shin J, Kim G-H, Park S, Ihm S-H, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25(1):20.CrossRefPubMedPubMedCentral Lee H-Y, Shin J, Kim G-H, Park S, Ihm S-H, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25(1):20.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Wyck DV, Bunnapradist S, Horwich TB. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation [Internet]. 2009;119(5):671–9. [cited 2016 Mar 18].CrossRef Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Wyck DV, Bunnapradist S, Horwich TB. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation [Internet]. 2009;119(5):671–9. [cited 2016 Mar 18].CrossRef
29.
Zurück zum Zitat Lindberg M, PRÜTZ K, Lindberg P, Wikström B. Interdialytic weight gain and ultrafiltration rate in hemodialysis: lessons about fluid adherence from a national registry of clinical practice. Hemodial Int. 2009;13(2):181–8.CrossRefPubMed Lindberg M, PRÜTZ K, Lindberg P, Wikström B. Interdialytic weight gain and ultrafiltration rate in hemodialysis: lessons about fluid adherence from a national registry of clinical practice. Hemodial Int. 2009;13(2):181–8.CrossRefPubMed
30.
Zurück zum Zitat Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int. 2007;11(1):21–31.CrossRefPubMed Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int. 2007;11(1):21–31.CrossRefPubMed
31.
Zurück zum Zitat Verberne WR, Dijkers J, Kelder JC, Geers ABM, Jellema WT, Vincent HH, et al. Value-based evaluation of dialysis versus conservative care in older patients with advanced chronic kidney disease: A cohort study. BMC Nephrol. 2018;19(1):1–11.CrossRef Verberne WR, Dijkers J, Kelder JC, Geers ABM, Jellema WT, Vincent HH, et al. Value-based evaluation of dialysis versus conservative care in older patients with advanced chronic kidney disease: A cohort study. BMC Nephrol. 2018;19(1):1–11.CrossRef
Metadaten
Titel
Conservative therapy is associated with worse clinical features and biochemical derangements than renal replacement therapy: a retrospective study in Kumasi, Ghana
verfasst von
Perditer Okyere
Isaac Okyere
Grace Essuman
Joseph Attakora
Dorcas Serwaa
Irene Esi Donkoh
Richard K.D. Ephraim
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Nephrology / Ausgabe 1/2022
Elektronische ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02951-z

Weitere Artikel der Ausgabe 1/2022

BMC Nephrology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.